TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26036434

Group type: EXPERIMENTAL
Intervention: Melatonin 1 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 23941889

Group type: EXPERIMENTAL
Intervention: STN‐DBS ON stimulation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: STN‐DBS OFF stimulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy adults
Number of subjects: 18
Study: 21308579

Group type: EXPERIMENTAL
Intervention: Food product ads employing nutrition claims with an anchor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anchoring successfully evoked
Number of subjects: 0
Study: 19850691

Group type: EXPERIMENTAL
Intervention: MMI+IID (Methimazole combined with intrathyroid injection of dexamethasone)
Number of subjects: 191

Group type: COMPARATOR
Intervention: MMI (Methimazole alone)
Number of subjects: 191
Study: 17304779

Group type: EXPERIMENTAL
Intervention: Inhaled isopropyl alcohol (IPA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ondansetron, 4 mg intravenously (Control)
Number of subjects: 100
Study: 15066931

Group type: EXPERIMENTAL
Intervention: +ISO (soy protein drink providing 83 mg/day isoflavones)
Number of subjects: 128

Group type: COMPARATOR
Intervention: -ISO (similar drink with isoflavones removed)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: +ISO
Number of subjects: 128

Group type: COMPARATOR
Intervention: -ISO
Number of subjects: 128
Study: 11755456

Group type: EXPERIMENTAL
Intervention: 2 g/day ethyl eicosapentaenoate (E‐E)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 4 g/day ethyl eicosapentaenoate (E‐E)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 9673662

Group type: EXPERIMENTAL
Intervention: fMRI
Number of subjects: 9

Group type: COMPARATOR
Intervention: PET
Number of subjects: 9
Study: 7640117

Group type: EXPERIMENTAL
Intervention: Transdermal hyoscine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 2376409

Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide (PB)
Number of subjects: 21
Study: 367234

Group type: EXPERIMENTAL
Intervention: Smoked marijuana
Number of subjects: 8

Group type: COMPARATOR
Intervention: Propranolol pretreatment
Number of subjects: 8
Study: 29160303

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 1822

Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 1822
Study: 28945881

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (alloHCT)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Postremission chemotherapy
Number of subjects: 497
Study: 26234442

Group type: EXPERIMENTAL
Intervention: Insulin detemir (Levemir) and biphasic insulin (NovoMix70)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Standard care according to the American Diabetes Association recommendations
Number of subjects: 245
Study: 23278837

Group type: EXPERIMENTAL
Intervention: Oscillating Pressure Infusion (OPI) method
Number of subjects: 47
Study: 21627685

Group type: EXPERIMENTAL
Intervention: Grade 1 hypoglycaemia (blood glucose < 4 mmol/l with no associated symptoms)
Number of subjects: 226

Group type: COMPARATOR
Intervention: No experience of hypoglycaemia
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Symptomatic hypoglycaemia (grade 2 and 3)
Number of subjects: 226
Study: 19085723

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50-150 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Fluvoxamine and Placebo)
Number of subjects: 60
Study: 16872336

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 51

Group type: COMPARATOR
Intervention: Balanced salt solution (Control)
Number of subjects: 51
Study: 12756382

Group type: EXPERIMENTAL
Intervention: Albuterol (0.1 mg/kg/dose) three times per day for 7 days
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo three times per day for 7 days
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 11123495

Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg testosterone enanthanate, intramuscularly every 2 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (intramuscularly every 2 weeks)
Number of subjects: 22
Study: 10968046

Group type: EXPERIMENTAL
Intervention: 1.2 g of Augmentin intravenously
Number of subjects: 200

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 200
Study: 8467321

Group type: EXPERIMENTAL
Intervention: Captopril (ACE-inhibition)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2946486

Group type: EXPERIMENTAL
Intervention: Wanbei
Number of subjects: 304

Group type: COMPARATOR
Intervention: Chuanbei
Number of subjects: 304
Study: 31610337

Group type: EXPERIMENTAL
Intervention: Tacrolimus suppositories (2mg, n=43)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Beclomethasone suppositories (3mg, n=42)
Number of subjects: 85
Study: 30308384

Group type: EXPERIMENTAL
Intervention: RAW (Benzodiazepine-resistant alcohol withdrawal)
Number of subjects: 736
Study: 26608876

Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine (40 mg) without sufentanil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine (40 mg) with sufentanil (1 μg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: hyperbaric bupivacaine (7.5 mg) with sufentanil (1 μg)
Number of subjects: 60
Study: 25038357

Group type: EXPERIMENTAL
Intervention: tesamorelin, 2 mg, subcutaneously daily for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study: 23233650

Group type: EXPERIMENTAL
Intervention: 1500 mg lapatinib for 28-42 days before surgery
Number of subjects: 31
Study: 21388821

Group type: EXPERIMENTAL
Intervention: Pulsatile pulmonary perfusion (PPP) with oxygenated blood
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional CPB
Number of subjects: 30
Study: 18636367

Group type: EXPERIMENTAL
Intervention: Diet rich in unprocessed fruits and vegetables
Number of subjects: 11

Group type: COMPARATOR
Intervention: High bioaccessible diet (animal foods and fruit juices)
Number of subjects: 11
Study: 16597662

Group type: EXPERIMENTAL
Intervention: Yellow tinted intraocular lenses (HOYA YA60BB)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Non-tinted intraocular lenses (VA60BB)
Number of subjects: 74
Study: 12651787

Group type: EXPERIMENTAL
Intervention: GP-initiated pre-conception counselling
Number of subjects: 1206
Study: 10882838

Group type: EXPERIMENTAL
Intervention: Chronic amphetamine abusers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic heroin abusers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 8635446

Group type: EXPERIMENTAL
Intervention: Weight level at 8.2 kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Weight level at 3 kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Weight level at 1.5 kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Weight level at 0.25 kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Weight levels (0.01, 0.5, 1, and 15 kg) considered for further analysis
Number of subjects: 12
Study: 1546413

Group type: EXPERIMENTAL
Intervention: Transdermally applied scopolamine (Scopoderm)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 50
Study: 2887941

Group type: EXPERIMENTAL
Intervention: captopril 25 mg twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: atenolol 100 mg once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: labetalol 200 mg twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: pindolol 10 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 31755321

Group type: EXPERIMENTAL
Intervention: Ripretinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study: 29200066

Group type: EXPERIMENTAL
Intervention: Global longitudinal strain
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Global longitudinal strain rate (SR)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 86
Study: 27955636

Group type: EXPERIMENTAL
Intervention: Preventative intervention program targeting personality traits associated with adolescent alcohol use
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cognitive tasks and neuroimaging scans conducted at baseline, 24-month, and 48-month follow-up
Number of subjects: 150
Study: 24691844

Group type: EXPERIMENTAL
Intervention: ACT-462206 200 mg and above
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ACT-462206 400-1000 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Almorexant 400 mg
Number of subjects: 44
Study: 22878561

Group type: EXPERIMENTAL
Intervention: Vitamins (with or without minerals)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Fish oil/omega-3 polyunsaturated fatty acids
Number of subjects: 235
Study: 20394831

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 156
Study: 18377400

Group type: EXPERIMENTAL
Intervention: Midazolam (10 mg increments, i.m. or i.v., at 10 min intervals, up to four doses)
Number of subjects: 62
Study: 16544318

Group type: EXPERIMENTAL
Intervention: ASC-H with HPV testing
Number of subjects: 5060

Group type: EXPERIMENTAL
Intervention: ASC-H
Number of subjects: 5060
Study: 12719802

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (0.5 mg/ml) perfusion before implantation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (Euro-Collins solution without AA)
Number of subjects: 31
Study: 10362452

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (Group CM, n = 9)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination of calcium pyruvate (60%) and creatine (40%) (Group COM, n = 11)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Calcium pyruvate (Group P, n = 11)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (Group PL)
Number of subjects: 42
Study: 7574045

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Endotracheal Tube
Number of subjects: 20
Study: 2126394

Group type: EXPERIMENTAL
Intervention: NORPLANT‐2 rod system
Number of subjects: 0

Group type: COMPARATOR
Intervention: NORPLANT six capsule system
Number of subjects: 0
Study: 527347

Group type: EXPERIMENTAL
Intervention: 20 microgram clenbuterol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 200 microgram salbutamol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31269409

Group type: EXPERIMENTAL
Intervention: Mymo Tracker
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Apple Watch 2
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Misfit Shine 2 (right hip)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Samsung Gear Fit 2
Number of subjects: 89

Group type: COMPARATOR
Intervention: Fitbit Charge 2
Number of subjects: 89
Study: 31908438

Group type: EXPERIMENTAL
Intervention: Mini-trampoline training program
Number of subjects: 20
Study: 29083221

Group type: EXPERIMENTAL
Intervention: Participants told they carried elevated genetic susceptibility to depression
Number of subjects: 887

Group type: COMPARATOR
Intervention: Participants told they did not carry genetic liability to depression or carried susceptibility to a different disorder
Number of subjects: 887
Study: 25431052

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg and 8 mg
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg, 4 mg, or 8 mg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 301
Study: 23810265

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Relaxation therapy (RT)
Number of subjects: 147
Study: 21453381

Group type: EXPERIMENTAL
Intervention: 8-week muscle strength exercise intervention focused on lower limb strength exercises of light to moderate intensity (30-70% of one repetition maximum, 1RM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 8-week muscle strength exercise intervention focused on lower limb strength exercises of light to moderate intensity
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study: 18778905

Group type: EXPERIMENTAL
Intervention: Oxygen-ozone combined with collagenase injection
Number of subjects: 108

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 108
Study: 16917950

Group type: EXPERIMENTAL
Intervention: methylphenidate (OROS and immediate release preparations)
Number of subjects: 106
Study: 15310251

Group type: EXPERIMENTAL
Intervention: Health assessments (annual or 6-monthly) by health professionals with telephone follow-up and written report to a general practitioner
Number of subjects: 1569

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1569
Study: 11547717

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (5 Gy on each of five days) followed by total mesorectal excision
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Total mesorectal excision alone
Number of subjects: 1805

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy plus total mesorectal excision
Number of subjects: 1805
Study: 9251545

Group type: EXPERIMENTAL
Intervention: Atenolol (25 mg)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 mg)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg)
Number of subjects: 868
Study: 8347750

Group type: EXPERIMENTAL
Intervention: Leaving messages on telephone answering machines
Number of subjects: 191

Group type: COMPARATOR
Intervention: No message
Number of subjects: 191
Study: 3327150

Group type: EXPERIMENTAL
Intervention: Single dose of 100 mg ofloxacin
Number of subjects: 137

Group type: COMPARATOR
Intervention: Multiple dose of cotrimoxazole
Number of subjects: 137
Study: 28836716

Group type: EXPERIMENTAL
Intervention: Real education (taste recognition test of supra‐ and sub‐threshold tastands)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham education
Number of subjects: 28
Study: 26993252

Group type: EXPERIMENTAL
Intervention: Bionic Pancreas (BP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 19
Study: 22909265

Group type: COMPARATOR
Intervention: sham rTMS
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: temporal rTMS (1 Hz over left auditory cortex)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: combined frontal and temporal rTMS (20 Hz over left frontal cortex followed by 1 Hz over left auditory cortex)
Number of subjects: 192
Study: 23889039

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 149

Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 149
Study: 20870179

Group type: EXPERIMENTAL
Intervention: 3.5 mm staple height
Number of subjects: 357

Group type: COMPARATOR
Intervention: 4.8 mm staple height
Number of subjects: 357
Study: 18390493

Group type: EXPERIMENTAL
Intervention: Placebo acupuncture alone (limited)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Placebo acupuncture with augmented patient-practitioner relationship (augmented)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Waiting list (observation)
Number of subjects: 262
Study: 16751644

Group type: EXPERIMENTAL
Intervention: Specialist contraceptive advice and enhanced provision
Number of subjects: 613

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 613
Study: 12890370

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) solution, equal to estimated blood loss (EBL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LRS), equal to three times the EBL
Number of subjects: 42
Study: 10523748

Group type: EXPERIMENTAL
Intervention: Beta-carotene arm (treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No beta-carotene arm (control)
Number of subjects: 0
Study: 8724088

Group type: EXPERIMENTAL
Intervention: Patients with spinal deformity due to tuberculosis
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal adult volunteers
Number of subjects: 26
Study: 1764952

Group type: EXPERIMENTAL
Intervention: Ofloxacin tablet (200 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ofloxacin tablet (300 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ofloxacin solution (200 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ofloxacin solution (300 mg)
Number of subjects: 32
Study: 7121050

Group type: EXPERIMENTAL
Intervention: Postoperative iron therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: No iron therapy
Number of subjects: 37
Study: 31721173

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 626

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 626
Study: 30924071

Group type: EXPERIMENTAL
Intervention: Daily oral medication
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: One injection per month
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 31-39 injections once every 3 months
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Oral medications (adverse events)
Number of subjects: 400
Study: 30063901

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate injection
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo injection (0.9% saline)
Number of subjects: 76
Study: 27555198

Group type: EXPERIMENTAL
Intervention: 50 μg morphine
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 100 μg morphine
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 50 μg morphine + 75 μg clonidine
Number of subjects: 195
Study: 25467394

Group type: EXPERIMENTAL
Intervention: Body weight-supported treadmill training (BWSTT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Overground gait training
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combined groups (BWSTT and overground gait training)
Number of subjects: 43
Study: 23046005

Group type: EXPERIMENTAL
Intervention: 5 ml mouthwash
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 10 ml mouthwash
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 15 ml mouthwash
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 20 ml mouthwash
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 30 ml mouthwash
Number of subjects: 62
Study: 19933538

Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg/kg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg/kg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sugammadex 8.0 mg/kg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sugammadex (various doses)
Number of subjects: 102
Study: 17881290

Group type: EXPERIMENTAL
Intervention: Short-term androgen deprivation (STAD) plus radiotherapy
Number of subjects: 586

Group type: COMPARATOR
Intervention: Long-term androgen deprivation (LTAD) plus radiotherapy
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: COX‐2 expression (as a continuous covariate)
Number of subjects: 586
Study: 15982134

Group type: EXPERIMENTAL
Intervention: Probabilistic category feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deterministic category feedback
Number of subjects: 0
Study: 11823753

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (normal strength)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Orange juice (normal strength)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Apple juice (normal strength)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (25% strength)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study: 9737819

Group type: EXPERIMENTAL
Intervention: Avitriptan 50 mg capsule administered under fasted condition and at various intervals (30 min, 1, 2, and 4 h) after a standard high fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avitriptan 50 mg capsule administered after a high protein and a high carbohydrate meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avitriptan 50 mg 14C-labeled solution administered after a standard high fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avitriptan 150 mg capsule administered after a standard high fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine pretreatment before avitriptan administration
Number of subjects: 0
Study: 8032702

Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone
Number of subjects: 63

Group type: COMPARATOR
Intervention: Metoclopramide plus dexamethasone plus diphenhydramine
Number of subjects: 63
Study: 2920503

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 31
Study: 31537118

Group type: EXPERIMENTAL
Intervention: Low neuroticism
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High extraversion
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High conscientiousness
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Personality traits
Number of subjects: 200
Study: 29687674

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal tube (iLTS‐D)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intubating laryngeal mask (iLMA)
Number of subjects: 30
Study: 27756322

Group type: EXPERIMENTAL
Intervention: Postoperative oral elemental diet (Elental®, 300 kcal/day)
Number of subjects: 43
Study: 24732649

Group type: EXPERIMENTAL
Intervention: Modified Figueroa technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Modified Grayson technique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 30
Study: 22556178

Group type: EXPERIMENTAL
Intervention: Alcohol and 1 mg citric acid
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Alcohol alone
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 20119583

Group type: EXPERIMENTAL
Intervention: Neurocognitive tests administered to schizophrenia patients
Number of subjects: 114

Group type: COMPARATOR
Intervention: Neurocognitive tests administered to healthy controls
Number of subjects: 114